As per reports, it has been revealed that Swiss drugmaker Roche Holden AG has stopped the drug trial of dalcetrapib, which would have fetched them $10 billion in the form of annual sales. The Data and Safety Monitoring Board was the one, which recommended stopping the trial as it was deriving the desired benefit.

The drug was meant to enhance the existing standard of care among patients, who have been suffering from heart disease. Kepler analyst Martin Voegtli was of the view that the elimination of Roche from manufacturing such an important heart disease medicine is a big loss for the company.

He further affirmed that if Roche would have got green signal for the trials, then there is no doubt that they would have become a leader in the cardiovascular market. "We anticipate a negative reaction driven by bad sentiment and we see other programs at risk as this is the second failure in this class following Pfizer's Torcetrapib", said Exane BNP Paribas analysts.

The only positive point of the drug is that there will be no more sales force costs, which have been associated with the drug. The news has brought a decline in the sales of Roche and they have gone down by 3.3%.